Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression

Siba El Elhussein, MD, L. Jeffrey Medeiros, MD, Kirill A. Lyapichev, MD, Stephen K. Gruschkus, PhD MPH, Peng Wei, PhD, Ellen Schlette, MD, Warren Fiskus, BSc,PhD, Rashmi Kanagal-Shamanna, MD, Sanam Loghavi, MD, Hong Yang, MD PhD, Shaoying Li, MD, Jie Xu, MD, Zhenya Tang, MD PhD, Beenu Thakral, MD, Nitin Jain, MD, William G. Wierda, MD PhD, Keyur Patel, MD PhD, Kapil N. Bhalla, MD, Joseph D. Khoury, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143122

Published: 2020

Journal Articles

Characteristics and Prognosis of Patients with Aggressive Chronic Lymphocytic Leukemia and Richter's Transformation: Correlation Between FDG/PET, Histology and Clinical Outcomes

Lorenzo Falchi, MD, Long Xuan Trinh, Edith M. Marom, MD, Mylene Truong, MD, Ellen Schlette, MD, Rachel L. Sargent, MD, Xuemei Wang, MS, Susan C. Smith, Susan Lerner, MS, Michael J. Keating, MD, Alessandra Ferrajoli, MD

Blood (2012) 120 (21): 927.

https://doi.org/10.1182/blood.V120.21.927.927

Published: 2012

Journal Articles

Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial

Alessandra Ferrajoli, MD, Susan O'Brien, MD, William G. Wierda, MD, PhD, Stefan Faderl, MD, Xavier Badoux, MD, Zeev Estrov, Ellen Schlette, MD, Susan C. Smith, BS, Ana B. Ayala, ADN, Lorenzo Falchi, MD, Steliana Calin, MD, Hagop M. Kantarjian, MD, Michael J Keating, MD

Blood (2011) 118 (21): 1788.

https://doi.org/10.1182/blood.V118.21.1788.1788

Published: 2011

Journal Articles

Myelodysplastic Syndrome with Fibrosis: Experience of a Single-Institution with 139 Patients.

Fabio P.S. Santos, MD, Ellen Schlette, MD, Hagop Kantarjian, MD, Rachel Sargent, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, PhD, Tapan Kadia, MD, Elias Jabbour, MD, Sherry Pierce, Gautam Borthakur, MD

Blood (2009) 114 (22): 2775.

https://doi.org/10.1182/blood.V114.22.2775.2775

Published: 2009

Journal Articles

Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patients with CLL Receiving Salvage Treatment.

Jerry D Henderson, MD, Susan M O’Brien, MD, Xuemei Wang, MS, Stefan H Faderl, MD, Alessandra Ferrajoli, MD, Guillermo Garcia-Manero, MD, Constantine S. Tam, MB.BS, Jan A Burger, MD, PhD, Lynne V Abruzzo, MD, PhD, Ellen Schlette, MD, Susan Lerner, Michael J Keating, MBBS, William G Wierda, MD, PhD

Blood (2008) 112 (11): 2078.

https://doi.org/10.1182/blood.V112.11.2078.2078

Published: 2008

Journal Articles

High T-Cell Lymphoma Breakpoint 1 (TCL1) Levels Are Associated with Lack of Response and Inferior Outcome Following Fludarabine, Cyclophosphamide, Rituximab (FCR) Frontline Therapy in Patients with Chronic Lymphocytic Leukemia (CLL).

Ellen Schlette, MD, Constantine S. Tam, MB.BS, Marco Herling, MD, Carlos Bueso-Ramos, MD, PhD, William Wierda, MD, Alessandra Ferrajoli, MD, Susan O’Brien, MD, Michael Keating, MB.BS, Dan Jones

Blood (2008) 112 (11): 2086.

https://doi.org/10.1182/blood.V112.11.2086.2086

Published: 2008

Journal Articles

Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy.

William G Wierda, MD, PhD, Susan M O’Brien, MD, Xuemei Wang, MS, Stefan H Faderl, MD, Alessandra Ferrajoli, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD, Constantine S Tam, MBBS, Jan A Burger, MD, PhD, Lynne V Abruzzo, MD, PhD, Ellen Schlette, MD, Susan Lerner, Michael J Keating, MBBS

Blood (2008) 112 (11): 2094.

https://doi.org/10.1182/blood.V112.11.2094.2094

Published: 2008

Journal Articles

The Clinical Usefulness of Novel Prognostic Factors in CLL: A Study of 477 Patients with Low-Risk (Non-11q, Non-17p) FISH and Known IGVH Mutation Status.

Constantine S. Tam, MBBS, Michael J. Keating, MD, Apostolia M. Tsimberidou, MD, Susan O’Brien, MD, Alessandra Tsimberidou, MD, Susan Lerner, MS, Lynne Abruzzo, MD, Ellen Schlette, MD, Hagop Kantarjian, MD, William Wierda, MD

Blood (2007) 110 (11): 3079.

https://doi.org/10.1182/blood.V110.11.3079.3079

Published: 2007

Journal Articles

Outcomes in Patients with Splenic Marginal Zone Lymphoma or Marginal Zone Leukemia/Lymphoma Treated with Immunotherapy, Chemoimmunotherapy, or Chemotherapy.

Apostolia-Maria Tsimberidou, MD, PhD, Daniel Catovsky, MD, Ellen Schlette, MD, Susan O’Brien, MD, BA, Hagop Kantarjian, MD, William G. Wierda, MD, PhD, Sijin Wen, MS, Susan Lerner, MS, BA, Michael J. Keating, MD

Blood (2005) 106 (11): 922.

https://doi.org/10.1182/blood.V106.11.922.922

Published: 2005

Journal Articles

Rituximab Plus GM-CSF for Patients with Chronic Lymphocytic Leukemia.

Alessandra Ferrajoli, MD, Susan M. O’Brien, MD, Stefan H. Faderl, MD, William G. Wierda, MD, PhD, Farhad Ravandi-Kashani, M.B.BS, Brandi O’Neal, BSN, Ellen Schlette, MD, Maher Albitar, MD, Hagop M. Kantarjian, MD, Michael J. Keating, M.B.BS

Blood (2005) 106 (11): 721.

https://doi.org/10.1182/blood.V106.11.721.721

Published: 2005

Journal Articles

TCL1 Expression in B-Cell Tumors Is Dynamically Regulated by Maturation Stage, Proliferation, and the Follicular Microenvironment.

Marco Herling, MD, Ryuji Kobayashi, PhD, Kaushali A. Patel, MS, Kong Chao Chang, MD, Ellen Schlette, MD, George Z. Rassidakis, MD, L. Jeffrey Medeiros, MD, Dan Jones, MD, PhD

Blood (2004) 104 (11): 4333.

https://doi.org/10.1182/blood.V104.11.4333.4333

Published: 2004

NARROW

Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression

Characteristics and Prognosis of Patients with Aggressive Chronic Lymphocytic Leukemia and Richter's Transformation: Correlation Between FDG/PET, Histology and Clinical Outcomes

Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial

Myelodysplastic Syndrome with Fibrosis: Experience of a Single-Institution with 139 Patients.

Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patients with CLL Receiving Salvage Treatment.

High T-Cell Lymphoma Breakpoint 1 (TCL1) Levels Are Associated with Lack of Response and Inferior Outcome Following Fludarabine, Cyclophosphamide, Rituximab (FCR) Frontline Therapy in Patients with Chronic Lymphocytic Leukemia (CLL).

Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy.

The Clinical Usefulness of Novel Prognostic Factors in CLL: A Study of 477 Patients with Low-Risk (Non-11q, Non-17p) FISH and Known IGVH Mutation Status.

Outcomes in Patients with Splenic Marginal Zone Lymphoma or Marginal Zone Leukemia/Lymphoma Treated with Immunotherapy, Chemoimmunotherapy, or Chemotherapy.

Rituximab Plus GM-CSF for Patients with Chronic Lymphocytic Leukemia.

TCL1 Expression in B-Cell Tumors Is Dynamically Regulated by Maturation Stage, Proliferation, and the Follicular Microenvironment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only